Multi-Pathway NAD+ Formulation to Limit CD38 Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations for boosting NAD+ in humans are rate-limited and do not account for degradation/consumption pathways, limiting their efficacy.
Innovation Solution
A triple boost formulation combining NAD precursors, boosters, and inhibitors to enhance NAD+ production and retention through multiple metabolic pathways, including NAD precursors like nicotinic acid and tryptophan, NAD boosters like NR and NMN, and CD38 inhibitors like quercetin and apigenin, with specific dosage ranges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If single pathway NAD+ boosters are used, then formulation simplicity is maintained, but NAD+ production is rate-limited and efficacy is constrained
Solution Approach 1:
The formulation is segmented into three distinct functional components: NAD+ precursors (nicotinic acid, tryptophan), NAD+ boosters (NR, NMN), and CD38 inhibitors (quercetin, apigenin, PNGL). Each component targets a specific pathway or mechanism, allowing independent optimization of each segment while achieving synergistic effects when combined, thereby resolving the contradiction between simplicity and productivity.
Solution Approach 2:
Multiple NAD+ boosting pathways are merged into a single formulation by combining precursors, boosters, and inhibitors that act through different metabolic routes. This merging allows simultaneous activation of multiple pathways (de novo synthesis, precursor conversion, and degradation inhibition) to overcome rate-limiting steps and achieve higher overall NAD+ production than any single pathway could provide.
2Quantity of substance
If NAD+ boosters are administered without inhibitors, then formulation simplicity is maintained, but NAD+ is rapidly degraded by CD38 enzyme
Solution Approach 1:
CD38 inhibitors (quercetin, apigenin, PNGL) are included in the formulation to preemptively block the enzymatic degradation pathway before NAD+ can be consumed. This preliminary anti-action against CD38 enzyme activity prevents the rapid degradation that would otherwise occur, thereby preserving NAD+ levels and extending its functional half-life in the body.
Solution Approach 2:
The harmful effect of CD38 enzyme activity, which naturally degrades NAD+, is converted into a beneficial strategy by using selective inhibitors. Instead of attempting to outpace degradation through sheer quantity of NAD+ administered, the formulation leverages inhibitory compounds to neutralize the degradation mechanism, transforming a harmful metabolic pathway into a controlled and manageable process.
3Productivity
If multiple ingredients are combined to boost NAD+ through different pathways, then NAD+ production efficacy is improved, but formulation complexity increases
Solution Approach 1:
The formulation achieves multi-functionality by incorporating ingredients that serve multiple purposes: for example, quercetin acts both as a CD38 inhibitor and as an antioxidant; apigenin similarly inhibits CD38 while providing anti-inflammatory effects; and the combination of precursors and boosters provides redundant pathways for NAD+ synthesis. This universality allows the formulation to address multiple metabolic needs simultaneously, improving overall efficacy while managing complexity through functional integration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Significantly increases NAD+ levels by up to two-fold compared to single pathway interventions, providing enhanced cellular function and potential health benefits.
Implementation Method 1
combining at least 3 and possibly 4 different ingredients that each use a distinct metabolic pathway
Implementation Method 2
inhibitors to keep NAD+ from being metabolized
Data Source
AI summary
Orally-ingestible supplement formulations for boosting Nicotinamide adenine dinucleotide (NAD+) in a human. The formulations provide a triple boost for NAD+ that will provide a) NAD+ boosters to increase natural production, b) a source of NAD+ and c) inhibitors to keep NAD+ from being metabolized. The formulations have one of each of: 1) an NAD precursor and/or reduced NAD precursor, 2) an NAD booster, 3) a CD38 Inhibitor, and 4) Reduced NAD precursors.